Core Insights - TG Therapeutics reported total revenue of $141.1 million for Q2 2025, with BRIUMVI U.S. net revenue at $138.8 million, reflecting a 91% increase year-over-year and a 16% increase from Q1 2025 [1][5][36] - The company raised its full-year 2025 BRIUMVI U.S. net revenue target to approximately $570 - $575 million, up from a previous guidance of $560 million [1][5] - TG Therapeutics is focused on the commercialization of BRIUMVI, which is gaining traction as a leading anti-CD20 therapy for relapsing multiple sclerosis (MS) [2][5] Financial Performance - BRIUMVI U.S. net product revenue for Q2 2025 was $138.8 million, marking a 91% growth compared to Q2 2024 and a 16% increase over Q1 2025 [5][36] - Total revenue for the first half of 2025 reached $262 million, compared to $136.9 million in the same period of 2024 [36] - The company reported a net income of $28.2 million for Q2 2025, compared to a net income of $6.9 million in Q2 2024 [11][36] Pipeline and Development - TG Therapeutics is advancing its pipeline with ongoing clinical trials, including a Phase 3 trial for a consolidated Day 1 and Day 15 dosing regimen for IV BRIUMVI [5][11] - The company has commenced patient enrollment for a Phase 1 clinical trial evaluating azer-cel for autoimmune diseases [5][11] - BRIUMVI has been approved for commercialization in the European Union, United Kingdom, Switzerland, and Australia, expanding its market reach [5][11] Market Position and Strategy - The company emphasizes the strong uptake of BRIUMVI, supported by physician confidence and positive patient experiences, which are critical to its launch strategy [2][5] - Innovations such as a subcutaneous formulation and combined dosing regimens are being studied to enhance BRIUMVI's market position [2][5] - TG Therapeutics aims to redefine treatment expectations for patients with MS through its strategic initiatives and product offerings [2][5]